Steven L. Hoerter - 14 Feb 2023 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc.

Role: President and CEO, Director
Signature: /s/ Jeffrey M. Held, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 14 Feb 2023
Net transactions value: -$480,720
Form type: 4
Filing time: 16 Feb 2023, 15:18:46 UTC
Previous filing: 17 Jun 2022
Next filing: 23 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DCPH	Common Stock	Sale	$480,720	-30,045	-80%	$16.00	7,500	14 Feb 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DCPH	Stock Option (Right to Buy)	Award	$0	+250,000		$0.000000	250,000	15 Feb 2023	Common Stock	250,000	$15.48	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale of shares reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2022.
F2	This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four (4) years, beginning on March 15, 2023.